Oxytocin and Dopamine's Effect on Vicarious Optimism

NCT03891095 | Completed

• 1 other identifier: OT-DA-Vicarious optimism
• Study Type: interventional
• Target: 156
• Locations: 1 country
• Sites: 1

Brief Summary

To investigate the effect of intranasal Oxytocin and L-DOPA's effect on vicarious optimism.

Conditions

Oxytocin Group; L-DOPA Group; Placebo Group

Keywords

intranasal oxytocin; L-DOPA; Vicarious optimism

Outcome Measures

Primary Outcomes (1)

• Belief update value for self, friend and stranger

  In the vicarious optimistic bias task, participants would make first estimation about the happening likelihood for each event for themselves, friend, and stranger and then receive feedback about the general likelihood of each event happened in future. After all events first estimation, participants would estimate all the event again. So, for the belief update, we used the second estimation value to minus the first estimation value to get the update value, as well as calculating the update value in desirable condition (first estimation \< feedback) and undesirable condition (first estimation \< feedback). Then investigated the general belief updating (gBU) and optimistic belief updating (using desirableBU-undesirableBU) for the three target (self vs. friend vs. stranger) in three treatment groups (Oxytocin vs. L-DOPA vs. Placebo)

  40~70 minutes after drug administration

Study Arms (3)

Intranasal oxytocin

EXPERIMENTAL

Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland)

Drug: Oxytocin; Drug: Placebos

L-DOPA

EXPERIMENTAL

L-DOPA, a neuropeptide who is a key modulator of complex socioaffective responses including reward, social decision making, learning. Subjects receiving 187.5 mg Madopar (L-DOPA treatment, including 150 mg L-3,4-dihydroxyphenylalanine, together with 37.5 mg benserazide, which promotes higher levels of dopamine in the brain while minimizing side effects from peripheral dopamine)

Drug: L-DOPA; Drug: Placebos

Placebo

PLACEBO COMPARATOR

Participants in the Placebo group received spray and oral placebos. 24 IU saline (spray placebo) 187.5 mg calcium carbonate (oral placebo)

Drug: Placebos

Interventions

Oxytocin DRUG

intranasally administrated

Intranasal oxytocin

L-DOPA DRUG

orally administered

L-DOPA

Placebos DRUG

intranasally administrated and orally administered

Intranasal oxytocin; L-DOPA; Placebo

Eligibility Criteria

• Gender Eligibility Details: we opted to recruit only males for the present study.
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• healthy subjects without past or current psychiatric or neurological disorders

You may not qualify if:

• subjects with past or current psychiatric or neurological disorders

Sponsors & Collaborators

• Beijing Normal University: lead
• Yale University: collaborator

Study Sites (1)

Beijing Normal University

Beijing, Beijing Municipality, 100000, China

Location

MeSH Terms

Interventions

Oxytocin; Levodopa

Intervention Hierarchy (Ancestors)

Pituitary Hormones, Posterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins; Dihydroxyphenylalanine; Catecholamines; Amines; Organic Chemicals; Catechols; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Phenylalanine; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids; Tyrosine

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: March 17, 2019
• First Posted: March 26, 2019
• Study Start: December 1, 2018
• Primary Completion: January 15, 2019
• Study Completion: January 16, 2019
• Last Updated: March 26, 2019

Record last verified: 2019-03

Locations

CN (1)